You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

OVIDE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Ovide, and what generic alternatives are available?

Ovide is a drug marketed by Taro and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has nine patent family members in six countries.

The generic ingredient in OVIDE is malathion. There are three drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the malathion profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Ovide

A generic version of OVIDE was approved as malathion by SUVEN PHARMS on May 23rd, 2012.

  Try a Trial

Paragraph IV (Patent) Challenges for OVIDE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
OVIDE Topical Lotion malathion 0.50% 018613 1 2011-03-16

US Patents and Regulatory Information for OVIDE

OVIDE is protected by two US patents.

Patents protecting OVIDE

Process for preparing malathion for pharmaceutical use
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF PATIENTS INFECTED WITH PEDICULUS HUMANUS CAPITIS (HEAD LICE AND THEIR OVA) OF THE SCALP HAIR

Process for preparing malathion for pharmaceutical use
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Taro OVIDE malathion LOTION;TOPICAL 018613-001 Aug 2, 1982 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
Taro OVIDE malathion LOTION;TOPICAL 018613-001 Aug 2, 1982 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for OVIDE

See the table below for patents covering OVIDE around the world.

Country Patent Number Title Estimated Expiration
China 103087095 Process for preparing malathion for pharmaceutical use, and combination thereof ⤷  Try a Trial
Japan 5474347 ⤷  Try a Trial
European Patent Office 1898707 PROCEDE DE PREPARATION DE MALATHION DESTINE A UN USAGE PHARMACEUTIQUE (PROCESS FOR PREPARING MALATHION FOR PHARMACEUTICAL USE) ⤷  Try a Trial
Canada 2612578 PROCEDE DE PREPARATION DE MALATHION DESTINE A UN USAGE PHARMACEUTIQUE (PROCESS FOR PREPARING MALATHION FOR PHARMACEUTICAL USE) ⤷  Try a Trial
China 101287374 Process for preparing malathion for pharmaceutical use ⤷  Try a Trial
World Intellectual Property Organization (WIPO) 2007005988 ⤷  Try a Trial
Japan 2013032405 PROCESS FOR PREPARING MALATHION FOR PHARMACEUTICAL USE ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.